These are the 4 learning objectives:

• Evaluate the clinical efficacy, safety, and role of pyrimethamine-

based therapy compared with trimethoprim-sulfamethoxazole for

the treatment of toxoplasmosis​

• Assess the risks of fluoroquinolone use in patients with prolonged

QTc to support safe, evidence-based antimicrobial selection​

• Determine when MRSA nares screening results can be considered for

guiding antimicrobial de-escalation in infections beyond pneumonia​

• Apply pharmacokinetic and clinical evidence to evaluate the role of

cefazolin in the management of central nervous system infections​